Takeda Steps Up Antibody Focus With U.S. Collaborator
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical, through its San Francisco subsidiary, has decided to increase its U.S. focus on developing therapeutic antibodies with U.S.-based Xoma. The plan includes increasing collaboration among all of its laboratories, both domestic and foreign. Takeda San Francisco intends to concentrate its efforts in the antibody field, taking advantage of a recent agreement to Xoma to use its advanced technologies and data-management systems. The pact calls for Takeda to choose compounds to study and Xoma to create antibodies for them. (Click here for more - a subscription may be required